Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Director | May 11, 2017 | May 12, 2017 |
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 13, 2023 | June 15, 2023 |
| G1 Therapeutics, Inc.GTHX · Entity 87413 | 10% owner | May 30, 2018 | June 01, 2018 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | June 16, 2022 | June 21, 2022 |
| PhaseBio Pharmaceuticals IncPHAS · Entity 113305 | 10% owner | October 22, 2018 | October 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aralez Pharmaceuticals Inc.
Report date May 11, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 102,952 |
Reported balance
After 2017-05-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-11 · Grant · Acquired 7,500 · Balance 102,952 F1: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date. F2: Includes 95,452 shares of Common Stock and 7,500 Restricted Stock Units. |
| Director Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.56 · Expires 2027-05-11 | Direct | 15,000 |
Reported balance
After 2017-05-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-11 · Grant · Acquired 15,000 · Balance 15,000 F3: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date.
F2: Includes 95,452 shares of Common Stock and 7,500 Restricted Stock Units.
F3: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date.
BIOCRYST PHARMACEUTICALS INC
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,863 |
Reported balance
After 2023-06-13 transaction · row 1
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 16,745 · Balance 68,863 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $8.18 · Expires 2033-06-13 | Direct | 39,072 |
Reported balance
After 2023-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-13 · Grant · Acquired 39,072 · Balance 39,072 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
G1 Therapeutics, Inc.
Report date May 30, 2018 · Filed June 01, 2018
Jointly reported with Thorp Clay, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Partners IV SBIC, LP, INGRAM ROBERT ALEXANDER, Crumpler John, Reed Douglas MD
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,279,421 |
Reported balance
After 2018-05-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-05-30 · Sale · Disposed 758,290 · Balance 3,279,421 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,237,711 |
Reported balance
After 2018-05-30 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-05-30 · Sale · Disposed 41,710 · Balance 3,237,711 F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein. F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC. F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV. |
Filing footnotes · ownership attribution and instrument terms
F1: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras Venture Advisors V, LLC ("HVA V") were sold, 995 shares of the reportable securities are owned directly by HVA V. The securities directly held by HVA V are indirectly held by the individual managing members of HVA V (each, a "Managing Member" and collectively, the "Managing Members"). The Managing Members are John Crumpler, Clay Thorp, Christy Shaffer, Douglas Reed and Robert Ingram. The Managing Members may share voting and dispositive power over the securities directly held by HVA V. Each Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.
F2: Following the reported transaction, 3,067,962 shares of the reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC ("HVA IV SBIC") is the general partner of HVP IV. The securities directly held by HVP IV are indirectly held by the individual managing members of HVA IV SBIC (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F3: Following the reported transaction, in which none of the reportable securities owned directly by Hatteras NC Fund, LP ("Hatteras NC") were sold, 210,464 shares of the reportable securities are owned directly by Hatteras NC. Hatteras Venture Advisors IV, LLC ("HVA IV") is the general partner of Hatteras NC. The securities directly held by Hatteras NC are indirectly held by the individual managing members of HVA IV (each, a "HVA IV Managing Member"). The HVA IV Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The HVA IV Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each HVA IV Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any HVA IV Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his or her pecuniary interest therein.
F4: Following the reported transaction, 168,754 shares of the reportable securities are owned directly by Hatteras NC.
F5: Following the reported transaction, in which none of the reportable securities owned directly by HVP IV were sold, 3,067,962 shares of the reportable securities are owned directly by HVP IV.
HYPERION DEFI, INC.
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 64,544 |
Reported balance
After 2022-06-16 transaction · row 1
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 22,222 · Balance 64,544 F1: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-06-16 | Direct | 30,769 |
Reported balance
After 2022-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-16 · Grant · Acquired 30,769 · Balance 30,769 F2: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
PhaseBio Pharmaceuticals Inc
Report date October 22, 2018 · Filed October 24, 2018
Jointly reported with Hatteras Venture Advisors III, LLC, Hatteras Ventures Partners III LP, Hatteras Venture Affiliates III Lp, Hatteras Venture Partners I, LP, Catalysta Ventures, LLC, Venture Capital Multiplier Fund, INGRAM ROBERT ALEXANDER, Reed Douglas MD, Crumpler John
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Hatteras Venture Partners I, LP | 52,690 |
Reported balance
After 2018-10-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-10-22 · Conversion · Acquired 52,690 · Balance 52,690 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Common StockSEC Table I · non-derivative | IndirectBy Hatteras Venture Partners III, LP | 1,820,933 |
Last balance in matching sequence
After 2018-10-22 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2018-10-22 · Conversion · Acquired 1,683,420 · Balance 1,683,420 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Row 3 · 2018-10-22 · Purchase · Acquired 137,513 · Balance 1,820,933 F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Common StockSEC Table I · non-derivative | IndirectBy Hatteras Venture Affiliates III, LP | 163,099 |
Last balance in matching sequence
After 2018-10-22 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 4 · 2018-10-22 · Conversion · Acquired 150,612 · Balance 150,612 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Row 5 · 2018-10-22 · Purchase · Acquired 12,487 · Balance 163,099 F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Common StockSEC Table I · non-derivative | IndirectBy Catalysta Ventures, LLC | 4,846 |
Reported balance
After 2018-10-22 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2018-10-22 · Conversion · Acquired 4,846 · Balance 4,846 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Common StockSEC Table I · non-derivative | IndirectBy Venture Capital Multiplier Fund | 416,481 |
Last balance in matching sequence
After 2018-10-22 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 7 · 2018-10-22 · Conversion · Acquired 266,481 · Balance 266,481 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Row 8 · 2018-10-22 · Purchase · Acquired 150,000 · Balance 416,481 F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Warrants to Purchase Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-10-22 · Other · Disposed 19,061 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 1,045,222 |
Reported balance
After 2018-10-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-10-22 · Other · Acquired 19,061 · Balance 1,045,222 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 1,044,764 |
Reported balance
After 2018-10-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-10-22 · Sale · Disposed 458 · Balance 1,044,764 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · 2018-10-22 · Conversion · Disposed 1,044,764 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Warrants to Purchase Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-10-22 · Other · Disposed 1,731 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 94,916 |
Reported balance
After 2018-10-22 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-10-22 · Other · Acquired 1,731 · Balance 94,916 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 94,874 |
Reported balance
After 2018-10-22 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-10-22 · Sale · Disposed 42 · Balance 94,874 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · 2018-10-22 · Conversion · Disposed 94,874 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-10-22 · Other · Disposed 47,458 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 150,459 |
Reported balance
After 2018-10-22 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-10-22 · Other · Acquired 47,458 · Balance 150,459 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 149,320 |
Reported balance
After 2018-10-22 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-10-22 · Sale · Disposed 1,139 · Balance 149,320 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 32
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 32 · 2018-10-22 · Conversion · Disposed 149,320 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2018-10-22 · Other · Disposed 4,309 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 13,662 |
Reported balance
After 2018-10-22 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2018-10-22 · Other · Acquired 4,309 · Balance 13,662 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 13,558 |
Reported balance
After 2018-10-22 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2018-10-22 · Sale · Disposed 104 · Balance 13,558 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 33
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 33 · 2018-10-22 · Conversion · Disposed 13,558 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Warrants to Purchase Series C-1 Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 | IndirectBy Venture Capital Multiplier Fund | 0 |
Reported balance
After 2018-10-22 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2018-10-22 · Other · Disposed 41,414 · Balance 0 F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Venture Capital Multiplier Fund | 41,414 |
Reported balance
After 2018-10-22 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2018-10-22 · Other · Acquired 41,414 · Balance 41,414 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Venture Capital Multiplier Fund | 40,420 |
Reported balance
After 2018-10-22 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2018-10-22 · Sale · Disposed 994 · Balance 40,420 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Venture Capital Multiplier Fund | 0 |
Reported balance
After 2018-10-22 transaction · row 34
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 34 · 2018-10-22 · Conversion · Disposed 40,420 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series 1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners I, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2018-10-22 · Conversion · Disposed 52,690 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series 1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2018-10-22 · Conversion · Disposed 42,530 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series 1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2018-10-22 · Conversion · Disposed 3,862 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series 1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Catalysta Ventures, LLC | 0 |
Reported balance
After 2018-10-22 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2018-10-22 · Conversion · Disposed 4,846 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series AA Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2018-10-22 · Conversion · Disposed 174,699 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series AA Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2018-10-22 · Conversion · Disposed 13,609 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Partners III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 35
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 35 · 2018-10-22 · Conversion · Disposed 272,107 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy Hatteras Venture Affiliates III, LP | 0 |
Reported balance
After 2018-10-22 transaction · row 36
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 36 · 2018-10-22 · Conversion · Disposed 24,709 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy Venture Capital Multiplier Fund | 0 |
Reported balance
After 2018-10-22 transaction · row 37
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 37 · 2018-10-22 · Conversion · Disposed 226,061 · Balance 0 F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
F2: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
F3: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately.
F4: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
F5: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Clearside Biomedical, Inc.
Report date January 17, 2017 · Filed January 19, 2017
Jointly reported with Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Partners IV SBIC, LP, Crumpler John, INGRAM ROBERT ALEXANDER, Reed Douglas MD, Thorp Clay
Section 16 reporting ended · disclosed 2017-01-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,060,514 |
Last balance in matching sequence
After 2017-01-19 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2017-01-17 · Sale · Disposed 9,806 · Balance 2,080,364 F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 2 · 2017-01-18 · Sale · Disposed 12,258 · Balance 2,068,106 F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 3 · 2017-01-19 · Sale · Disposed 7,592 · Balance 2,060,514 F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $8.68 to $9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F3: This transaction was executed in multiple trades at prices ranging from $8.42 to $8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F4: This transaction was executed in multiple trades at prices ranging from $8.01 to $8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2023 Filed Jun 15, 2023 20:42 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 39,072 | $0.00 Strike: $8.18 | $0.00 |
DisclosureSEC source: 0001127602-23-018791 · form4.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,072 Underlying: Common Stock · 39,072 shares Expires 2033-06-13 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:42 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 16,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018791 · form4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,863 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:15 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 15,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001127602-23-003163 · form4.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person engaged in a non-market, cash exercise and hold transaction with respect to these stock options and the underlying shares. The options were originally granted to the reporting person on May 31, 2013 and would have expired on May 31, 2023. No sales of the issuer's common stock have occurred as part of this transaction. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:15 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 15,000 | $1.71 | $25,650.00 |
DisclosureSEC source: 0001127602-23-003163 · form4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person engaged in a non-market, cash exercise and hold transaction with respect to these stock options and the underlying shares. The options were originally granted to the reporting person on May 31, 2013 and would have expired on May 31, 2023. No sales of the issuer's common stock have occurred as part of this transaction. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 14:19 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 30,769 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001415889-22-006807 · form4-06212022_110619.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,769 Underlying: Common Stock · 30,769 shares Expires 2032-06-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 14:19 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 22,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006807 · form4-06212022_110619.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,544 F1 · shares: Represents restricted stock units that fully vest on the earlier of June 16, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,022 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001127602-22-017144 · form4.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,022 Underlying: Common Stock · 30,022 shares Expires 2032-06-07 F2 · security: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 12,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017144 · form4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,118 F1 · shares: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. Read SEC document |
| May 19, 2022 Filed May 23, 2022 08:49 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 10,000 | $2.20 | $22,000.00 |
DisclosureSEC source: 0001415889-22-005467 · form4-05232022_050528.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,322 Read SEC document |
| November 17, 2021 Filed Nov 22, 2021 09:09 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,653 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001415889-21-005357 · form4-11222021_061146.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2031-11-17 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| November 17, 2021 Filed Nov 22, 2021 09:09 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 6,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005357 · form4-11222021_061146.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,322 F1 · shares: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:26 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionAutomatic Stock Option Grant · Derivative | 15,000 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001127602-21-025331 · form4.xml · derivative · entry 3 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:26 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 6,000 | $15.35 | $92,100.00 |
DisclosureSEC source: 0001127602-21-025331 · form4.xml · nonDerivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,252 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.24 to $15.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:26 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 15,000 | $3.22 | $48,300.00 |
DisclosureSEC source: 0001127602-21-025331 · form4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 15, 2021 16:26 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 2,000 | $5.41 | $10,812.00 |
DisclosureSEC source: 0001638599-21-000551 · doc4_7267.xml · nonDerivative · entry 3 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,359 Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 16:26 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 2,000 | $5.47 | $10,940.00 |
DisclosureSEC source: 0001638599-21-000551 · doc4_7267.xml · nonDerivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,359 Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:26 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | PurchaseCommon Stock, par value $.0001 | 2,000 | $5.38 | $10,760.00 |
DisclosureSEC source: 0001638599-21-000551 · doc4_7267.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,359 Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001127602-21-018186 · form4.xml · derivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-05-25 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:17 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,820 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001104659-20-105235 · tm2030853d4_4.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,820 Underlying: Common Stock · 9,820 shares Expires 2030-09-11 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| September 11, 2020 Filed Sep 15, 2020 16:17 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 7,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-105235 · tm2030853d4_4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,359 F1 · shares: Represents restricted stock units that vest on the earlier of September 11, 2021 or the date of the Issuer's 2021 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:31 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016575 · form4.xml · derivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 5,000 | $1.45 | $7,250.00 |
DisclosureSEC source: 0001127602-19-033029 · form4.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,252 Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 17:21 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,057 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001638599-19-000795 · doc4_6257.xml · derivative · entry 2 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,057 Underlying: Common Stock · 9,057 shares Expires 2029-08-16 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 17:21 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 8,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-19-000795 · doc4_6257.xml · nonDerivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,071 F1 · shares: Represents restricted stock units that vest on the earlier of August 16, 2020 or the date of the Issuer's 2020 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020314 · form4.xml · derivative · entry 1 LEE KENNETH B JR · CIK 0001208570 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries D Preferred Stock · Derivative | 226,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 37 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 0 Underlying: Common Stock · 226,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries D Preferred Stock · Derivative | 24,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 36 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 24,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries D Preferred Stock · Derivative | 272,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 35 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 272,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries C-1 Preferred Stock · Derivative | 40,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 34 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 0 Underlying: Common Stock · 40,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries C-1 Preferred Stock · Derivative | 13,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 33 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 13,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries C-1 Preferred Stock · Derivative | 149,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 32 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 149,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries B Preferred Stock · Derivative | 94,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 31 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 94,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries B Preferred Stock · Derivative | 1,044,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 30 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 1,044,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries AA Preferred Stock · Derivative | 13,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 29 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 13,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries AA Preferred Stock · Derivative | 174,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 28 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 174,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 4,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 27 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Catalysta Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 4,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 3,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 26 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Common Stock · 3,862 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 42,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 25 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Common Stock · 42,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | ConversionSeries 1 Preferred Stock · Derivative | 52,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 24 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners I, LP Disclosed balance after: 0 Underlying: Common Stock · 52,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: Catalysta Ventures, LLC ("Catalysta") is under common control with Hatteras Venture Advisors III, LLC ("HVA III"). Catalysta is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta, which may be deemed to share voting and dispositive power with regard to the securities directly held by HVP I. Catalysta disclaims beneficial ownership of the securities held by HVP I except to the extent of its pecuniary interest therein. The individual managers of Catalysta are Clay B. Thorp and John Crumpler (the "Managers"), who may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The Managers disclaim beneficial ownership of the securities held by Catalysta and HVP I except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries C-1 Preferred Stock · Derivative | 994 | $5.00 | $4,970.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 23 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 40,420 Underlying: Common Stock · 994 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherSeries C-1 Preferred Stock · Derivative | 41,414 | $0.12 | $4,969.68 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 22 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 41,414 Underlying: Common Stock · 41,414 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherWarrants to Purchase Series C-1 Preferred Stock · Derivative | 41,414 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 21 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Venture Capital Multiplier Fund Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 41,414 shares Expires not disclosed F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries C-1 Preferred Stock · Derivative | 104 | $5.00 | $520.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 20 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 13,558 Underlying: Common Stock · 104 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherSeries C-1 Preferred Stock · Derivative | 4,309 | $0.12 | $517.08 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 19 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 13,662 Underlying: Common Stock · 4,309 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherWarrants to Purchase Series C-1 Preferred Stock · Derivative | 4,309 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 18 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 4,309 shares Expires not disclosed F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries C-1 Preferred Stock · Derivative | 1,139 | $5.00 | $5,695.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 17 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 149,320 Underlying: Common Stock · 1,139 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherSeries C-1 Preferred Stock · Derivative | 47,458 | $0.12 | $5,694.96 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 16 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 150,459 Underlying: Common Stock · 47,458 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherWarrants to Purchase Series C-1 Preferred Stock · Derivative | 47,458 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 15 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Partners III, LP Disclosed balance after: 0 Underlying: Series C-1 Preferred Stock · 47,458 shares Expires not disclosed F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering. F1 · derivative.underlying: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | SaleSeries B Preferred Stock · Derivative | 42 | $5.00 | $210.00 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 14 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 94,874 Underlying: Common Stock · 42 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 16:18 UTC | PhaseBio Pharmaceuticals Inc PHAS · Entity 113305 | OtherSeries B Preferred Stock · Derivative | 1,731 | $0.12 | $207.72 |
DisclosureSEC source: 0001209191-18-056048 · doc4.xml · derivative · entry 13 Hatteras Venture Advisors III, LLC · CIK 0001674177 · 10% owner Hatteras Ventures Partners III LP · CIK 0001390733 · 10% owner Hatteras Venture Affiliates III Lp · CIK 0001390738 · 10% owner Hatteras Venture Partners I, LP · CIK 0001756231 · 10% owner Catalysta Ventures, LLC · CIK 0001756233 · 10% owner Venture Capital Multiplier Fund · CIK 0001756148 · 10% owner INGRAM ROBERT ALEXANDER · CIK 0001219890 · 10% owner LEE KENNETH B JR · CIK 0001208570 · 10% owner Reed Douglas MD · CIK 0001291262 · 10% owner Crumpler John · CIK 0001674107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Hatteras Venture Affiliates III, LP Disclosed balance after: 94,916 Underlying: Common Stock · 1,731 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F4 · kind: Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F1 · derivative.expiration_date: Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date. F3 · ownership.nature: HVA III is the general partner of Hatteras Venture Partners III, LP ("HVP III"), Hatteras Venture Affiliates III, LP ("HV Affiliates") and Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by HVP III, HV Affiliates and Multiplier Fund are indirectly held by HVA III. The individual managers of HVA III are Clay B. Thorp, Robert A. Ingram, Kenneth B. Lee, Douglas Reed, MD and John Crumpler (the "GP Directors"). HVA III and the GP Directors may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. HVA III and the GP Directors disclaim beneficial ownership of the securities held by HVP III, HV Affiliates and Multiplier Fund except to the extent of their pecuniary interest therein. Mr. Thorp is a director of the Issuer and files Section 16 reports separately. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.